Psychedelics LSD helps alleviate anxiety and major depression symptoms: MindMed Participants in a recent study saw statistically significant improvements in their MDD symptoms Rowan DunneApril 14, 2023
Psychedelics MindMed doses first patient with MDMA-like compounds in new trial New study will compare the effects of MDA and MDMA in humans for the first time Rowan DunneSeptember 20, 2022
Psychedelics MindMed announces initial patient dosing in MM-120 study Biopharmaceutical company administers optimized form of LSD in Phase 2b dose-optimization trial Rowan DunneAugust 25, 2022
Medical and Pharmaceutical Common antidepressant escitalopram and psilocybin can be taken together safely: study Research funded by MindMed suggests some antidepressants can reduce the unwanted side effects of psychedelics Natalia Buendia CalvilloDecember 1, 2021
News MindMed stock surges on Nasdaq listing approval After its stock jumped 66%, MindMed now rivals Compass Pathways as the world's most valuable psychedelic company Jared GnamApril 23, 2021
Psychedelics 2020’s top 5 advancements in psychedelics With major research, legal reform, and more than 20 firms going public, it was major year for the re-emerging field Jared GnamDecember 30, 2020